These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 33538152)

  • 1. Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study.
    Zayac AS; Evens AM; Danilov A; Smith SD; Jagadeesh D; Leslie LA; Wei C; Kim SH; Naik S; Sundaram S; Reddy N; Farooq U; Kenkre VP; Epperla N; Blum KA; Khan N; Singh D; Alderuccio JP; Godara A; Yazdy MS; Diefenbach C; Rabinovich E; Varma G; Karmali R; Shao Y; Trabolsi A; Burkart M; Martin P; Stettner S; Chauhan A; Choi YK; Straker-Edwards A; Klein A; Churnetski MC; Boughan KM; Berg S; Haverkos BM; Orellana-Noia VM; D'Angelo C; Bond DA; Maliske SM; Vaca R; Magarelli G; Sperling A; Gordon MJ; David KA; Savani M; Caimi P; Kamdar M; Lunning MA; Palmisiano N; Venugopal P; Portell CA; Bachanova V; Phillips T; Lossos IS; Olszewski AJ
    Haematologica; 2021 Jul; 106(7):1932-1942. PubMed ID: 33538152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial.
    Chamuleau MED; Stenner F; Chitu DA; Novak U; Minnema MC; Geerts P; Stevens WBC; Zenz T; van Imhoff GW; Wu KL; Demandt AMP; Kersten MJ; Terpstra WE; Tick LW; Deeren D; Van Den Neste E; Gregor M; Veelken H; Böhmer LH; Caspar CB; Mutsaers P; Refos JM; Sewsaran R; Fu L; Seefat RL; Uyl-de Groot CA; Dirnhofer S; Van Den Brand M; de Jong D; Nijland M; Lugtenburg P
    Lancet Haematol; 2023 Dec; 10(12):e966-e975. PubMed ID: 37922925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis.
    Alderuccio JP; Olszewski AJ; Evens AM; Collins GP; Danilov AV; Bower M; Jagadeesh D; Zhu C; Sperling A; Kim SH; Vaca R; Wei C; Sundaram S; Reddy N; Dalla Pria A; D'Angelo C; Farooq U; Bond DA; Berg S; Churnetski MC; Godara A; Khan N; Choi YK; Kassam S; Yazdy M; Rabinovich E; Post FA; Varma G; Karmali R; Burkart M; Martin P; Ren A; Chauhan A; Diefenbach C; Straker-Edwards A; Klein A; Blum KA; Boughan KM; Mian A; Haverkos BM; Orellana-Noia VM; Kenkre VP; Zayac A; Maliske SM; Epperla N; Caimi P; Smith SE; Kamdar M; Venugopal P; Feldman TA; Rector D; Smith SD; Stadnik A; Portell CA; Lin Y; Naik S; Montoto S; Lossos IS; Cwynarski K
    Blood Adv; 2021 Jul; 5(14):2852-2862. PubMed ID: 34283175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
    Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS
    Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy.
    Alwan F; He A; Montoto S; Kassam S; Mee M; Burns F; Edwards S; Wilson A; Tenant-Flowers M; Marcus R; Ardeshna KM; Bower M; Cwynarski K
    AIDS; 2015 May; 29(8):903-10. PubMed ID: 25730506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.
    McMillan AK; Phillips EH; Kirkwood AA; Barrans S; Burton C; Rule S; Patmore R; Pettengell R; Ardeshna KM; Lawrie A; Montoto S; Paneesha S; Clifton-Hadley L; Linch DC
    Ann Oncol; 2020 Sep; 31(9):1251-1259. PubMed ID: 32464282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.
    Evens AM; Carson KR; Kolesar J; Nabhan C; Helenowski I; Islam N; Jovanovic B; Barr PM; Caimi PF; Gregory SA; Gordon LI
    Ann Oncol; 2013 Dec; 24(12):3076-81. PubMed ID: 24146219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
    Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
    Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
    Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma.
    Corazzelli G; Frigeri F; Russo F; Frairia C; Arcamone M; Esposito G; De Chiara A; Morelli E; Capobianco G; Becchimanzi C; Volzone F; Saggese M; Marcacci G; De Filippi R; Vitolo U; Pinto A
    Br J Haematol; 2012 Jan; 156(2):234-44. PubMed ID: 22098541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse.
    Samra B; Khoury JD; Morita K; Ravandi F; Richard-Carpentier G; Short NJ; El Hussein S; Thompson P; Jain N; Kantarjian H; Jabbour E
    Blood Adv; 2021 Oct; 5(20):3913-3918. PubMed ID: 34464974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report.
    Goldman S; Smith L; Galardy P; Perkins SL; Frazer JK; Sanger W; Anderson JR; Gross TG; Weinstein H; Harrison L; Shiramizu B; Barth M; Cairo MS
    Br J Haematol; 2014 Nov; 167(3):394-401. PubMed ID: 25066629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma.
    Noy A; Lee JY; Cesarman E; Ambinder R; Baiocchi R; Reid E; Ratner L; Wagner-Johnston N; Kaplan L;
    Blood; 2015 Jul; 126(2):160-6. PubMed ID: 25957391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
    Roschewski M; Dunleavy K; Abramson JS; Powell BL; Link BK; Patel P; Bierman PJ; Jagadeesh D; Mitsuyasu RT; Peace D; Watson PR; Hanna WT; Melani C; Lucas AN; Steinberg SM; Pittaluga S; Jaffe ES; Friedberg JW; Kahl BS; Little RF; Bartlett NL; Fanale MA; Noy A; Wilson WH
    J Clin Oncol; 2020 Aug; 38(22):2519-2529. PubMed ID: 32453640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B-cell lymphoma in the rituximab era.
    Vassilakopoulos TP; Panitsas F; Mellios Z; Apostolidis J; Michael M; Gurion R; Ferhanoglu B; Hatzimichael E; Karakatsanis S; Dimou M; Kalpadakis C; Katodritou E; Leonidopoulou T; Kotsianidis I; Giatra H; Kanellias N; Sayyed A; Tadmor T; Akay OM; Angelopoulou MK; Horowitz N; Bakiri M; Pangalis GA; Panayiotidis P; Papageorgiou SG
    Hematol Oncol; 2023 Feb; 41(1):97-107. PubMed ID: 36314897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Burkitt lymphoma - no impact of HIV status on outcomes with rituximab-based chemoimmunotherapy.
    Tan JY; Qiu TY; Chiang J; Tan YH; Yang VS; Chang EWY; Poon E; Somasundaram N; Farid M; Tao M; Lim ST; Chan JY
    Leuk Lymphoma; 2023 Mar; 64(3):586-596. PubMed ID: 35188049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment outcome in children with central nervous system-positive Burkitt lymphoma using only intrathecal and systemic chemotherapy combined with rituximab.
    Huang S; Jin L; Yang J; Duan YL; Zhang M; Zhou CJ; Zhang YH
    Chin Med J (Engl); 2021 Mar; 134(11):1329-1334. PubMed ID: 33734131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.
    Maruyama D; Watanabe T; Maeshima AM; Nomoto J; Taniguchi H; Azuma T; Mori M; Munakata W; Kim SW; Kobayashi Y; Matsuno Y; Tobinai K
    Int J Hematol; 2010 Dec; 92(5):732-43. PubMed ID: 21120644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful salvage chemotherapy for isolated central nervous system (CNS) relapse in Burkitt lymphoma: monocentric experience of 3 pediatric patients.
    Baleydier F; Pondarre C; Pages MP; Mialou V; Kebaili K; Pracros JP; Bertrand Y
    J Pediatr Hematol Oncol; 2008 Dec; 30(12):972-5. PubMed ID: 19131795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.